BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11504741)

  • 1. Treatment of Waldenstrom's macroglobulinemia with thalidomide.
    Dimopoulos MA; Zomas A; Viniou NA; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotidis P
    J Clin Oncol; 2001 Aug; 19(16):3596-601. PubMed ID: 11504741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone.
    Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Margaritis D; Matsouka C; Economopoulos T; Anagnostopoulos N
    Semin Oncol; 2003 Apr; 30(2):265-9. PubMed ID: 12720150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Waldenström's macroglobulinemia with rituximab.
    Dimopoulos MA; Zervas C; Zomas A; Kiamouris C; Viniou NA; Grigoraki V; Karkantaris C; Mitsouli C; Gika D; Christakis J; Anagnostopoulos N
    J Clin Oncol; 2002 May; 20(9):2327-33. PubMed ID: 11981004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide is safe and active in Waldenström macroglobulinemia.
    Fouquet G; Guidez S; Petillon MO; Louni C; Ohyba B; Dib M; Poulain S; Herbaux C; Martin A; Thielemans B; Brice P; Choquet S; Bakala J; Bories C; Demarquette H; Nudel M; Tournilhac O; Arnulf B; LeGouill S; Morel P; Banos A; Karlin L; Salles G; Leblond V; Leleu X
    Am J Hematol; 2015 Nov; 90(11):1055-9. PubMed ID: 26284823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
    Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Chu L; Musto P; Baron AD; Nunnink JC; Kash JJ; Terjanian TO; Hyman PM; Nawfel EL; Sharon DJ; Munshi NC; Anderson KC
    Clin Cancer Res; 2009 Jan; 15(1):355-60. PubMed ID: 19118065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone.
    Coleman M; Leonard J; Lyons L; Szelenyi H; Niesvizky R
    Semin Oncol; 2003 Apr; 30(2):270-4. PubMed ID: 12720151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide and rituximab in Waldenstrom macroglobulinemia.
    Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Briccetti FM; Pasmantier M; Zimbler H; Cooper RB; Moore M; Hill J; Rauch A; Garbo L; Chu L; Chua C; Nantel SH; Lovett DR; Boedeker H; Sonneborn H; Howard J; Musto P; Ciccarelli BT; Hatjiharissi E; Anderson KC
    Blood; 2008 Dec; 112(12):4452-7. PubMed ID: 18713945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia.
    Coleman M; Leonard J; Lyons L; Pekle K; Nahum K; Pearse R; Niesvizky R; Michaeli J
    Leuk Lymphoma; 2002 Sep; 43(9):1777-82. PubMed ID: 12685831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine therapy in Waldenström's macroglobulinemia.
    Dimopoulos MA; O'Brien S; Kantarjian H; Pierce S; Delasalle K; Barlogie B; Alexanian R; Keating MJ
    Am J Med; 1993 Jul; 95(1):49-52. PubMed ID: 8328496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
    J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.
    Byrd JC; White CA; Link B; Lucas MS; Velasquez WS; Rosenberg J; Grillo-López AJ
    Ann Oncol; 1999 Dec; 10(12):1525-7. PubMed ID: 10643548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.
    Dimopoulos MA; Zervas C; Zomas A; Hamilos G; Gika D; Efstathiou E; Panayiotidis P; Vervessou E; Anagnostopoulos N; Christakis J
    Clin Lymphoma; 2002 Dec; 3(3):163-6. PubMed ID: 12521393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
    Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
    Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
    Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
    Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.
    Dimopoulos MA; Kantarjian H; Weber D; O'Brien S; Estey E; Delasalle K; Rose E; Cabanillas F; Keating M; Alexanian R
    J Clin Oncol; 1994 Dec; 12(12):2694-8. PubMed ID: 7989946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab-based treatments in Waldenström's macroglobulinemia.
    Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future directions in haematology: beyond multiple myeloma.
    Prentice HG; Sacchi S; Russell N
    Acta Haematol; 2005; 114 Suppl 1():27-32. PubMed ID: 16166770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended rituximab therapy in Waldenström's macroglobulinemia.
    Treon SP; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan AR; Anderson KC; Frankel SR;
    Ann Oncol; 2005 Jan; 16(1):132-8. PubMed ID: 15598950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
    Amato RJ; Sarao H
    Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.